The impact of antimicrobial resistance on health and economic outcomes

Sara Cosgrove, Yehuda Carmeli

Research output: Contribution to journalArticle

Abstract

Despite an increasing prevalence of antimicrobial-resistant pathogens, the health and economic impact of colonization and infection with these organisms has not been fully elucidated. We explore how antimicrobial resistance can affect patient outcomes by enhancing virulence, causing a delay in the administration of appropriate therapy, and limiting available therapy. Next, we examine the different perspectives held by hospitals, third-party payers, patients, and society on the impact of resistance. Finally, we review methodological issues in designing and assessing studies that address the clinical outcomes for patients infected or colonized with resistant pathogens, including adjustment for important confounding variables, control group selection, and the quantification of economic outcomes.

Original languageEnglish (US)
Pages (from-to)1433-1437
Number of pages5
JournalClinical Infectious Diseases
Volume36
Issue number11
DOIs
StatePublished - Jun 1 2003

Fingerprint

Economics
Health
Health Insurance Reimbursement
Confounding Factors (Epidemiology)
Virulence
Control Groups
Therapeutics
Infection
Clinical Studies

ASJC Scopus subject areas

  • Immunology

Cite this

The impact of antimicrobial resistance on health and economic outcomes. / Cosgrove, Sara; Carmeli, Yehuda.

In: Clinical Infectious Diseases, Vol. 36, No. 11, 01.06.2003, p. 1433-1437.

Research output: Contribution to journalArticle

@article{8e84b51814a341e39002f45fac377f0f,
title = "The impact of antimicrobial resistance on health and economic outcomes",
abstract = "Despite an increasing prevalence of antimicrobial-resistant pathogens, the health and economic impact of colonization and infection with these organisms has not been fully elucidated. We explore how antimicrobial resistance can affect patient outcomes by enhancing virulence, causing a delay in the administration of appropriate therapy, and limiting available therapy. Next, we examine the different perspectives held by hospitals, third-party payers, patients, and society on the impact of resistance. Finally, we review methodological issues in designing and assessing studies that address the clinical outcomes for patients infected or colonized with resistant pathogens, including adjustment for important confounding variables, control group selection, and the quantification of economic outcomes.",
author = "Sara Cosgrove and Yehuda Carmeli",
year = "2003",
month = "6",
day = "1",
doi = "10.1086/375081",
language = "English (US)",
volume = "36",
pages = "1433--1437",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - The impact of antimicrobial resistance on health and economic outcomes

AU - Cosgrove, Sara

AU - Carmeli, Yehuda

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Despite an increasing prevalence of antimicrobial-resistant pathogens, the health and economic impact of colonization and infection with these organisms has not been fully elucidated. We explore how antimicrobial resistance can affect patient outcomes by enhancing virulence, causing a delay in the administration of appropriate therapy, and limiting available therapy. Next, we examine the different perspectives held by hospitals, third-party payers, patients, and society on the impact of resistance. Finally, we review methodological issues in designing and assessing studies that address the clinical outcomes for patients infected or colonized with resistant pathogens, including adjustment for important confounding variables, control group selection, and the quantification of economic outcomes.

AB - Despite an increasing prevalence of antimicrobial-resistant pathogens, the health and economic impact of colonization and infection with these organisms has not been fully elucidated. We explore how antimicrobial resistance can affect patient outcomes by enhancing virulence, causing a delay in the administration of appropriate therapy, and limiting available therapy. Next, we examine the different perspectives held by hospitals, third-party payers, patients, and society on the impact of resistance. Finally, we review methodological issues in designing and assessing studies that address the clinical outcomes for patients infected or colonized with resistant pathogens, including adjustment for important confounding variables, control group selection, and the quantification of economic outcomes.

UR - http://www.scopus.com/inward/record.url?scp=0038806687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038806687&partnerID=8YFLogxK

U2 - 10.1086/375081

DO - 10.1086/375081

M3 - Article

VL - 36

SP - 1433

EP - 1437

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 11

ER -